Clinical trials: Septic Shock, completed
Severe Sepsis, Septic Shock
A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock
The two co-primary objectives of this study are to assess in Japanese patients with severe sepsis and/or septic shock: 1) the safety and tolerability of two different doses of intravenous AZD9773 and 2) the PK of AZD9773.
- Trial name
- NCT01144624
- Testing
- AZD9773
- Where
- 7 sites in Japan
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Severe Sepsis
ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis
The purpose of this study is to compare eritoran tetrasodium and placebo in patients with severe sepsis and to demonstrate a reduction of mortality from all causes.
- Trial name
- NCT00334828
- Testing
- eritoran tetrasodium
- Where
- 251 sites in United States, Argentina and 22 more
- Volunteers
- 2,000 people
- Sponsor
- Eisai Inc.
Septic Shock
Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock
The purpose of this trial is to investigate the potential of FE 202158 as a treatment which can stabilize blood pressure for treatment of patients in early septic shock.
- Trial name
- NCT01612676
- Testing
- FE 202158
- Where
- 4 sites in Belgium, Denmark
- Volunteers
- 31 people
- Sponsor
- Ferring Pharmaceuticals
Septic Shock, Endotoxemia
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
To compare the safety and efficacy of the PMX cartridge based on mortality at 28-days in subjects with septic shock who have high levels of endotoxin and are treated with standard medical care plus use of the PMX cartridge…
- Trial name
- EUPHRATES (NCT01046669)
- Testing
- TORAYMYXIN PMX-20R (PMX cartridge), Standard medical care for septic shock
- Where
- 40 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- Spectral Diagnostics (US) Inc.
Sepsis
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock
The purpose of this placebo-controlled study is to determine if drotrecogin alfa (activated) treatment provides significant mortality reduction improvement in patients with septic shock compared with placebo treatment in patients…
- Trial name
- NCT00604214
- Testing
- Drotrecogin alfa (activated)
- Where
- 150 sites in United States, Australia and 16 more
- Volunteers
- 1,696 people
- Sponsor
- Eli Lilly and Company
Septic Shock
Early Albumin Resuscitation During Septic Shock
Objective: To determine whether the early administration of albumin as an expander and antioxidant would improve survival on the 28th day for septic shock patients.
- Trial name
- NCT00327704
- Testing
- albumin, saline
- Where
- France
- Volunteers
- 794 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Severe Sepsis, Septic Shock
A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock
The primary purpose of this study to evaluate the effect of two different doses of AZD9773 (CytoFab™) versus placebo on ventilator free days (VFDs) over the first 28 days after the start of dosing with AZD9773 in patients with…
- Trial name
- NCT01145560
- Testing
- AZD9773
- Where
- 52 sites in Australia, Belgium and 5 more
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Peritonitis, Septic Shock
Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock
The purpose of this randomized, comparative, open and multi-centre study is to show that two sessions of hemoperfusion with Toraymyxin performed within maximum 36 hours after the surgery of a peritonitis by hollow organ…
- Trial name
- ABDO-MIX (NCT01222663)
- Testing
- standard therapy, hemoperfusion
- Where
- 18 sites in France
- Volunteers
- 243 people
- Sponsor
- Meditor SAS
Septic Shock
Efferon LPS Hemoperfusion for Treatment of Patients With Septic Shock
Sepsis is a global healthcare burden sepsis, it reaches 20-30 million cases annually (WHO data). Numerous studies have shown that extracorporeal hemoperfusion therapies that eliminate endotoxin and\or excess of cytokines improve…
- Trial name
- NCT04884854
- Testing
- Efferon LPS
- Where
- Russia
- Volunteers
- 9 people
- Sponsor
- Efferon JSC
Sepsis, Septic Shock
Predictive algoRithm for EValuation and Intervention in SEpsis
In this prospective study, the ability of a machine learning algorithm to predict sepsis and influence clinical outcomes, will be investigated at Cabell Huntington Hospital (CHH).
- Conditions
- Sepsis, Septic Shock, Severe Sepsis
- Trial name
- PREVISE (NCT03235193)
- Testing
- Severe Sepsis Prediction, Severe Sepsis Detection
- Where
- United States
- Volunteers
- 2,296 people
- Sponsor
- Dascena
Shock, Septic
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock
This is a randomised, double-blind, two-stage, placebo controlled study. It is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of nangibotide versus placebo in adult patients…
- Trial name
- NCT03158948
- Testing
- Nangibotide 0.3 mg/kg, Nangibotide 1 mg/kg, Nangibotide 3 mg/kg
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 50 people
- Sponsor
- Inotrem
Septic Shock
Lipopolysaccharide Adsorption At Septic Shock
Sepsis is a global healthcare burden sepsis, it reaches 20-30 million cases annually (WHO data). Numerous studies have shown that extracorporeal hemoperfusion therapies that eliminate endotoxin and\or excess of cytokines improve…
- Trial name
- LASSO (NCT04827407)
- Testing
- Efferon LPS hemoperfusion
- Where
- 4 sites in Russia
- Volunteers
- 58 people
- Sponsor
- Efferon JSC
Sepsis, Systemic Inflammatory Response Syndrome (SIRS)
VENUS: Septic Gene Expression Using SeptiCyte
The investigators seek to evaluate a new test for determining presence of infection/sepsis as compared to non-infection/systemic inflammatory response syndrome among critically ill patients within the first 24 hours of their…
- Trial name
- VENUS (NCT02127502)
- Where
- 6 sites in United States
- Volunteers
- 379 people
- Sponsor
- Immunexpress
Septic Shock, Sepsis
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
- Conditions
- Septic Shock, Sepsis, Hypovolemia
- Trial name
- VBI-S-02 (NCT06072430)
- Testing
- VBI-S
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Vivacelle Bio
Sepsis, Hypotension
Fluid Responsiveness Evaluation in Sepsis-associated Hypotension
This study assesses the mean difference in fluid balance at ICU discharge and associated patient outcomes, based on a dynamic assessment of fluid responsiveness in septic patients with refractory hypotension in an ICU setting.
- Trial name
- FRESH (NCT02837731)
- Testing
- Treatment Starling SV monitor
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cheetah Medical Inc.
Sepsis, Septic Shock
Combined Hemoperfusion and Therapeutic Plasma Exchange for Treatment of Patients With Septic Shock
Sepsis is a critical burden for a healthcare. From 2000 to 2020, the number of publications and clinical studies on the topic of Sepsis and septic shock on the National Library of Medicine resource The National Center for…
- Trial name
- NCT06404424
- Testing
- Efferon LPS, Efferon CT
- Where
- Russia
- Volunteers
- 82 people
- Sponsor
- Efferon JSC
Septic Shock, Endotoxemia
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
- Trial name
- TIGRIS (NCT03901807)
- Testing
- Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
- Where
- 20 sites in United States
- Volunteers
- 157 people
- Sponsor
- Spectral Diagnostics (US) Inc.
Severe Sepsis With Septic Shock
A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients
A multicenter, randomized, double-blinded, placebo-controlled study of two dosing frequencies of recombinant Interleukin-7 (CYT107) treatment to restore absolute lymphocyte counts in sepsis patients; IRIS-7B (Immune…
- Trial name
- IRIS-7-B (NCT02640807)
- Testing
- Interleukin-7
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Revimmune
Healthy Subjects
A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229
This is a Phase I, single-center, randomized, single-blind, placebo-controlled study in healthy subjects assessing the safety, tolerability and pharmacokinetic profile of three different dose levels of M6229 when administered…
- Trial name
- NCT07285603
- Testing
- M6229
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Matisse Pharmaceuticals
Sepsis, Septic Shock
An Algorithm Driven Sepsis Prediction Biomarker
A sepsis early warning predictive algorithm, InSight, has been developed and validated on a large, diverse patient cohort. In this prospective study, the ability of InSight to predict severe sepsis patients is investigated.
- Conditions
- Sepsis, Septic Shock, Severe Sepsis
- Trial name
- NCT03015454
- Testing
- Severe Sepsis Prediction, Severe Sepsis Detection
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Dascena